文献速递神经肿瘤

分子型与组织学型胶质母细胞瘤的对比分析:预后差异的深入探讨

Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance.
PubMed 文献 · J Neurooncol · 2024-08-08

该单中心回顾性研究纳入2005至2023年983例IDH野生型胶质母细胞瘤患者(分子型52例,组织学型931例),比较临床、分子、影像、手术因素及预后。分子型患者更年轻(58.1岁 vs 62.4岁,P=0.014),TERTp突变率更高(84.6% vs 50.3%,P<0.001),影像上大脑胶质瘤病模式发生率更高(32.7% vs 9.2%,P<0.001),导致切除程度更低(P<0.001)。分子型中位总生存期优于组织学型(30.2个月 vs 18.4个月,P=0.001),倾向性评分匹配后仍确认该优势(P<0.001)。

要点

  • 分子型胶质母细胞瘤患者较组织学型更年轻,TERTp突变率更高。
  • 分子型影像上大脑胶质瘤病模式更常见,导致手术切除程度更低。
  • 分子型中位总生存期优于组织学型(30.2 vs 18.4个月,P=0.001)。

核心结论

  • 分子型胶质母细胞瘤与组织学型在临床、分子和影像上存在明显差异,分子型预后更佳。

研究设计与样本

  • 单中心回顾性病历与影像回顾研究,纳入2005至2023年983例IDH野生型胶质母细胞瘤患者(分子型52例,组织学型931例),并进行倾向性评分匹配分析。

主要发现

  • 分子型患者年龄低于组织学型(58.1岁 vs 62.4岁,P=0.014)。
  • 分子型TERTp突变率高于组织学型(84.6% vs 50.3%,P<0.001)。
  • 分子型大脑胶质瘤病模式发生率高于组织学型(32.7% vs 9.2%,P<0.001),且切除程度更低(P<0.001)。
  • 分子型中位总生存期长于组织学型(30.2个月 vs 18.4个月,P=0.001),倾向性评分匹配后仍确认该优势(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Whether molecular glioblastomas (GBMs) identify with a similar dismal prognosis as a "classical" histological GBM is controversial. This study aimed to compare the clinical, molecular, imaging, surgical factors, and prognosis between molecular GBMs and histological GBMs. METHODS: Retrospective chart and imaging review was performed in 983 IDH-wildtype GBM patients (52 molecular GBMs and 931 histological GBMs) from a single institution between 2005 and 2023. Propensity score-matched analysis was additionally performed to adjust for differences in baseline variables between molecular GBMs and histological GBMs. RESULTS: Molecular GBM patients were substantially younger (58.1 vs. 62.4, P = 0.014) with higher rate of TERTp mutation (84.6% vs. 50.3%, P < 0.001) compared with histological GBM patients. Imaging showed higher incidence of gliomatosis cerebri pattern (32.7% vs. 9.2%, P < 0.001) in molecular GBM compared with histological GBM, which resulted in lesser extent of resection (P < 0.001) in these patients. The survival was significantly better in molecular GBM compared to histological GBM (median OS 30.2 vs. 18.4 months, P = 0.001). The superior outcome was confirmed in propensity score analyses by matching histological GBM to molecular GBM (P < 0.001). CONCLUSION: There are distinct clinical, molecular, and imaging differences between molecular GBMs and histological GBMs. Our results suggest that molecular GBMs have a more favorable prognosis than histological GBMs.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lee M, Karschnia P, Park YW, et al. Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance. J Neurooncol. 2024. PMID: 39115615. doi:10.1007/s11060-024-04737-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。